|
Boehringer Ingelheim Statement on Hepatitis C drug development
|
29 June 2014 |
|
Boehringer Ingelheim will make detailed clinical trial data available to the scientific community
|
14 May 2014 |
|
Pradaxa® (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation
|
06 March 2014 |
|
Boehringer Ingelheim receives East Bay Innovation Award
|
19 February 2014 |
|
Crystal Bioscience and Boehringer Ingelheim announce multiple target antibody discovery collaboration
|
10 February 2014 |
|
New study showed significant reduction in blood glucose with Linagliptin alone and in combination with metformin
|
04 December 2013 |
|
Global Lung Cancer Coalition to identify patient challenges and improve support strategies in partnership with Boehringer Ingelheim
|
28 October 2013 |
|
Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa® compared to warfarin
|
07 October 2013 |
|
Nintedanib* extended survival beyond one year for advanced adenocarcinoma patients after prior first-line chemotherapy
|
30 September 2013 |
|
Pradaxa® (dabigatran etexilate) drives Boehringer Ingelheim's innovation promise in cardiovascular diseases
|
05 September 2013 |
|
Benefits of Pradaxa® maintained in difficult to treat patients with atrial fibrillation and symptomatic heart failure
|
16 July 2013 |
|
Results of new meta-analysis regarding CV events in linagliptin Phase 3 trials
|
25 June 2013 |
|
Boehringer Ingelheim pioneers biopharmaceuticals move to China
|
06 June 2013 |
|
Boehringer Ingelheim and Eli Lilly & Company launch type 2 diabetes educational game, "Complications Combat"
|
26 May 2013 |
|
Boehringer Ingelheim joins Structural Genomics Consortium
|
08 May 2013 |
|
FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate)
|
26 March 2013 |
|
American College of Cardiology and Boehringer Ingelheim collaborate to advance physician education
|
10 March 2013 |
|
New findings from two studies support substantial benefit of Pradaxa®
|
21 February 2013 |
|
FDA grants priority review to Boehringer Ingelheim's Afatinib* NDA for EGFR mutation-positive advanced NSCLC
|
15 January 2013 |
|
Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin
|
07 January 2013 |